PAX8 by IHC

Alphabetical Test listing

PAX8 by IHC-12376 - Technical only, 12379 - Technical & interpretation

  
PAX8 by IHC
  
12376 - Technical only, 12379 - Technical & interpretation
  
LAB12376
LAB12379
  
  • All IHC stains will include a positive control tissue
  
  • PAX8 is expressed in ovarian serous (99%), endometrioid (98%), and clear cell carcinomas (78%) (and only very rarely in mucinous ovarian tumors), and cervical carcinomas (91%)
  • PAX8 is present in 90-98% of clear cell renal cell carcinomas, 90% of papillary renal cell carcinomas, and 81-95 % of oncocytomas
  • PAX8 is expressed in thyroid neoplasms (91%)
  • No (or focal weak) expression for PAX8 is seen in lung, breast, and non-GYN carcinomas
  • Thymic carcinomas and thymomas may show moderate staining with PAX8
  • PAX8 is useful in a panel differentiating peritoneal mesothelioma from papillary serous
  • PAX8 can be used to discriminate GYN tumors from breast tumors
  
Tissue
  

Submit a formalin-fixed, paraffin embedded tissue block

  

Formalin-fixed, paraffin embedded (FFPE) tissue block

  

FFPE tissue section mounted on a charged, unstained slide

  

Ambient (preferred)

  
  • Unlabeled/mislabeled block
  • Insufficient tissue
  • Slides broken beyond repair
  
AHL - Immunohistochemistry
  
Mo - Fr
  
1 - 2 days
  

Immunohistochemical staining and microscopic examination

  

If requested, an interpretive report will be provided

  

Specifications

  • PAX8 is a member of the PAX family of transcription factors that are active in thyroid development
  • PAX8 expression is seen in thyroid, non-ciliated mucosal cells of fallopian tubes, ovarian inclusion cysts, and in renal tubular cells and associated tumors
  • PAX8 positivity can be seen in B-cell lymphomas, likely due to cross reactivity with PAX5

 Staining pattern

  • Nuclear

References

  1. Laury AR et al: A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors Am J Surg Pathol 2011;35:816-826).
  2. Morgan EA at al: PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas. Histopathology 2013, 62, 406-413.
  3. Moretti L at al: N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Modern Pathology 2012, 25, 231-236.
  4. Ordonez NG: Value of PAX 8 Immunostaining in Tumor Diagnosis: A Review and Update. Adv Anat Pathol 2012;19:140-151).
  
88342 - 1st stain
88341 - each additional stain
  
08/07/2017
  
10/19/2018
  
10/02/2020